{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:54:16Z","timestamp":1791251656988,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100031570","name":"ALK-Abell\u00f3","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031570","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pollen from birch and other trees in the birch homologous group (e.g., oak) is a common trigger of allergic rhinitis and\/or conjunctivitis (AR\/C) in Canada. The efficacy and safety of the tree sublingual immunotherapy (SLIT)-tablet in children with AR\/C was evaluated post hoc in the Canadian subpopulation of a phase III, double-blind trial (EudraCT2020-004372-17).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Children and adolescents aged 5\u201317 years with moderate-to-severe tree AR\/C were randomized to either daily tree SLIT-tablet or placebo for up to 52 weeks. Participants had free access to symptom-relieving medication. The primary endpoint was the average total combined score (TCS; sum of rhinoconjunctivitis daily symptom score [DSS] and daily medication score [DMS]) during birch pollen season (BPS). Average TCS during tree pollen season (TPS, consisting of birch, alder, hazel, and oak pollen seasons), oak pollen season (OPS), and pure OPS (excluding days from birch, alder, or hazel pollen seasons) were also analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the Canadian subpopulation (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200987), treatment with the tree SLIT-tablet reduced the average TCS by 26.8% versus placebo during BPS (absolute difference [95% CI]\u2009=\u20091.89 [-0.71, 4.49],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.138), 32.0% during TPS (absolute difference\u2009=\u20092.14 [-0.03, 4.32],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.042), 46.6% during OPS (absolute difference\u2009=\u20093.70 [0.98, 6.42],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004), and 50.6% during pure OPS (absolute difference\u2009=\u20094.20 [1.12, 7.27],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005). Reductions in DSS and DMS with tree SLIT-tablet versus placebo were also observed.\n                    <\/jats:p>\n                    <jats:p>\n                      In the total trial population (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009952), tree SLIT-tablet treatment reduced the average TCS by 19.2% versus placebo during BPS (absolute difference\u2009=\u20091.13 [0.42, 1.84],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002), 16.8% during TPS (absolute difference\u2009=\u20090.76 [0.26, 1.26],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003), 23.4% during OPS (absolute difference\u2009=\u20091.32 [0.60, 2.05],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and 19.9% during pure OPS (absolute difference\u2009=\u20091.03 [0.27, 1.80],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.009). The tree SLIT-tablet was well tolerated in the total trial and Canadian subgroup populations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The tree SLIT-tablet demonstrated favorable efficacy and was well tolerated in Canadian children and adolescents with AR\/C.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>EudraCT 2020-004372-17 and NCT04878354.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13223-026-01054-w","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T01:54:46Z","timestamp":1783734886000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of the tree sublingual immunotherapy tablet in the subpopulation of Canadian children with allergic rhinitis and\/or conjunctivitis: phase III trial results"],"prefix":"10.1186","volume":"22","author":[{"given":"R\u00e9mi","family":"Gagnon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terrie","family":"Dalgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gry Schermann","family":"Ortving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Gappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Nolte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"1054_CR1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.1365-2222.1997.tb00672.x","volume":"27","author":"LP Boulet","year":"1997","unstructured":"Boulet LP, Turcotte H, Laprise C, Lavertu C, B\u00e9dard PM, Lavoie A, et al. Comparative degree and type of sensitization to common indoor and outdoor allergens in subjects with allergic rhinitis and\/or asthma. Clin Exp Allergy. 1997;27:52\u20139.","journal-title":"Clin Exp Allergy"},{"key":"1054_CR2","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.3390\/ijerph15081577","volume":"15","author":"C Sierra-Heredia","year":"2018","unstructured":"Sierra-Heredia C, North M, Brook J, Daly C, Ellis AK, Henderson D, et al. Aeroallergens in Canada: Distribution, Public Health Impacts, and Opportunities for Prevention. Int J Environ Res Public Health. 2018;15:1577.","journal-title":"Int J Environ Res Public Health"},{"key":"1054_CR3","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1111\/j.1398-9995.2010.02399.x","volume":"65","author":"M Chan-Yeung","year":"2010","unstructured":"Chan-Yeung M, Anthonisen NR, Becklake MR, Bowie D, Sonia Buist A, Dimich-Ward H, et al. Geographical variations in the prevalence of atopic sensitization in six study sites across Canada. Allergy. 2010;65:1404\u201313.","journal-title":"Allergy"},{"key":"1054_CR4","unstructured":"Rankin B. Presence of birch. [Internet]. 2016 [cited 2025 December 12]. Available from: http:\/\/www.radicalcartography.net\/index.html?trees"},{"key":"1054_CR5","unstructured":"Presence of oak. [Internet]. Radical Cartography. 2016 [cited 2020 June 19]. Available from: http:\/\/www.radicalcartography.net\/index.html?trees"},{"key":"1054_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13223-019-0320-y","volume":"15","author":"H Ahmed","year":"2019","unstructured":"Ahmed H, Ospina MB, Sideri K, Vliagoftis H. Retrospective analysis of aeroallergen\u2019s sensitization patterns in Edmonton, Canada. Allergy Asthma Clin Immunol. 2019;15:6.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"Suppl 1","key":"1054_CR7","first-page":"A3","volume":"13","author":"A Ciccolini","year":"2017","unstructured":"Ciccolini A, Ellis AK. Nature and prevalence of environmental allergies in the Kingston, Ontario region. Allergy Asthma Clin Immunol. 2017;13(Suppl 1):A3.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"1054_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13223-017-0181-1","volume":"13","author":"SD Lok","year":"2017","unstructured":"Lok SD, Davis BE, Cockcroft DW. Prevalence of allergen sensitization in 1000 adults in Saskatchewan. Allergy Asthma Clin Immunol. 2017;13:9.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"1054_CR9","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/0161-5890(91)90015-C","volume":"28","author":"H Ipsen","year":"1991","unstructured":"Ipsen H, Hansen OC. The NH2-terminal amino acid sequence of the immunochemically partial identical major allergens of Alder (Alnus glutinosa) Aln g I, birch (Betula verrucosa) Bet v I, hornbeam (Carpinus betulus) Car b I and oak (Quercus alba) Que a I pollens. Mol Immunol. 1991;28:1279\u201388.","journal-title":"Mol Immunol"},{"key":"1054_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/all.13606","volume":"74","author":"P Couroux","year":"2019","unstructured":"Couroux P, Ipsen H, Stage BS, Damkjaer JT, Steffensen MA, Salapatek AM, et al. A birch sublingual allergy immunotherapy tablet reduces rhinoconjunctivitis symptoms when exposed to birch and oak and induces IgG4 to allergens from all trees in the birch homologous group. Allergy. 2019;74:361\u20139.","journal-title":"Allergy"},{"key":"1054_CR11","doi-asserted-by":"crossref","unstructured":"Ramirez RM, Jacobs RL, Andrews CP. Birch-naive, oak-allergic subjects\u2019 response to birch pollen in an environmental chamber. Allergy Asthma Proc. 2022;43:116\u2009\u2013\u200923.","DOI":"10.2500\/aap.2022.43.210097"},{"key":"1054_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1710-1492-8-7","volume":"8","author":"PK Keith","year":"2012","unstructured":"Keith PK, Desrosiers M, Laister T, Schellenberg RR, Waserman S. The burden of allergic rhinitis (AR) in Canada: perspectives of physicians and patients. Allergy Asthma Clin Immunol. 2012;8:7.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"1054_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13223-020-0412-8","volume":"16","author":"AK Ellis","year":"2020","unstructured":"Ellis AK, Boursiquot J, Carr S, Graham F, Masse MS. Patient and physician perceptions of seasonal allergic rhinitis and allergen immunotherapy: a parallel physician patient survey. Allergy Asthma Clin Immunol. 2020;16:15.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"1054_CR14","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1159\/000116360","volume":"146","author":"RE Dales","year":"2008","unstructured":"Dales RE, Cakmak S, Judek S, Coates F. Tree pollen and hospitalization for asthma in urban Canada. Int Arch Allergy Immunol. 2008;146:241\u20137.","journal-title":"Int Arch Allergy Immunol"},{"key":"1054_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12940-015-0057-0","volume":"14","author":"K Ito","year":"2015","unstructured":"Ito K, Weinberger KR, Robinson GS, Sheffield PE, Lall R, Mathes R, et al. The associations between daily spring pollen counts, over-the-counter allergy medication sales, and asthma syndrome emergency department visits in New York City, 2002\u20132012. Environ Health. 2015;14:71.","journal-title":"Environ Health"},{"key":"1054_CR16","doi-asserted-by":"publisher","first-page":"107998","DOI":"10.1016\/j.envint.2023.107998","volume":"177","author":"BL Lappe","year":"2023","unstructured":"Lappe BL, Ebelt S, D\u2019Souza RR, Manangan A, Brown C, Saha S, et al. Pollen and asthma morbidity in Atlanta: A 26-year time-series study. Environ Int. 2023;177:107998.","journal-title":"Environ Int"},{"key":"1054_CR17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13223-024-00935-2","volume":"20","author":"J-N Boursiquot","year":"2024","unstructured":"Boursiquot J-N, Gagnon R, Quirt J, Ellis AK. Allergen immunotherapy. Allergy Asthma Clin Immunol. 2024;20:66.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"1054_CR18","doi-asserted-by":"publisher","first-page":"1447619","DOI":"10.3389\/fped.2024.1447619","volume":"12","author":"K Rance","year":"2024","unstructured":"Rance K, Blaiss M, Gupta P, Nolte H, Scott EP, Gardner DD. Degree of fear of needles and preferred allergy immunotherapy treatment among children with allergic rhinitis: Caregiver survey results. Front Ped. 2024;12:1447619.","journal-title":"Front Ped"},{"key":"1054_CR19","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/all.16363","volume":"80","author":"M Gappa","year":"2025","unstructured":"Gappa M, Gagnon R, Horak F, Cichocka-Jarosz E, Dalgaard T, Hargreaves K, et al. The SQ tree sublingual immunotherapy tablet is effective and well tolerated in children-A pivotal phase III trial. Allergy. 2025;80:795\u2013806.","journal-title":"Allergy"},{"key":"1054_CR20","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/all.14111","volume":"75","author":"O Pfaar","year":"2020","unstructured":"Pfaar O, Karatzas K, Bastl K, Berger U, Buters J, Darsow U, et al. Pollen season is reflected on symptom load for grass and birch pollen-induced allergic rhinitis in different geographic areas-An EAACI Task Force Report. Allergy. 2020;75:1099\u2013106.","journal-title":"Allergy"},{"key":"1054_CR21","first-page":"982","volume":"21","author":"SW Blume","year":"2015","unstructured":"Blume SW, Yeomans K, Allen-Ramey F, Smith N, Kim H, Lockey RF, et al. Administration and Burden of Subcutaneous Immunotherapy for Allergic Rhinitis in U.S. and Canadian Clinical Practice. J Manag Care Spec Pharm. 2015;21:982\u201390.","journal-title":"J Manag Care Spec Pharm"},{"key":"1054_CR22","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/1744666X.2017.1277142","volume":"13","author":"U Wahn","year":"2017","unstructured":"Wahn U, Calderon MA, Demoly P. Real-life clinical practice and management of polysensitized patients with respiratory allergies: a large, global survey of clinicians prescribing allergen immunotherapy. Expert Rev Clin Immunol. 2017;13:283\u20139.","journal-title":"Expert Rev Clin Immunol"},{"key":"1054_CR23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13223-021-00626-2","volume":"17","author":"AK Ellis","year":"2021","unstructured":"Ellis AK, Gagnon R, Bernstein DI, Nolte H. Randomized controlled trial of ragweed sublingual immunotherapy tablet in the subpopulation of Canadian children and adolescents with allergic rhinoconjunctivitis. Allergy Asthma Clin Immunol. 2021;17:127.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"1054_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1710-1492-10-53","volume":"10","author":"J Hebert","year":"2014","unstructured":"Hebert J, Blaiss M, Waserman S, Kim H, Creticos P, Maloney J, et al. The efficacy and safety of the Timothy grass allergy sublingual immunotherapy tablet in Canadian adults and children. Allergy Asthma Clin Immunol. 2014;10:53.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"1054_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1710-1492-10-55","volume":"10","author":"H Kim","year":"2014","unstructured":"Kim H, Waserman S, H\u00e9bert J, Blaiss M, Nelson H, Creticos P, et al. Efficacy and safety of ragweed sublingual immunotherapy in Canadian patients with allergic rhinoconjunctivitis. Allergy Asthma Clin Immunol. 2014;10:55.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"1054_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000355630","volume":"163","author":"D Caillaud","year":"2014","unstructured":"Caillaud D, Martin S, Segala C, Besancenot JP, Clot B, Thibaudon M. Effects of airborne birch pollen levels on clinical symptoms of seasonal allergic rhinoconjunctivitis. Int Arch Allergy Immunol. 2014;163:43\u201350.","journal-title":"Int Arch Allergy Immunol"},{"key":"1054_CR27","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10453-011-9221-3","volume":"28","author":"J Jantunen","year":"2012","unstructured":"Jantunen J, Saarinen K, Rantio-Lehtimaki A. Allergy symptoms in relation to alder and birch pollen concentrations in Finland. Aerobiologia. 2012;28:169\u201376.","journal-title":"Aerobiologia"},{"key":"1054_CR28","first-page":"225","volume":"86","author":"E Taudorf","year":"1988","unstructured":"Taudorf E, Moseholm L. Pollen count, symptom and medicine score in birch pollinosis. A mathematical approach. Int Arch Allergy Appl Immunol. 1988;86:225\u201333.","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"1054_CR29","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/j.1365-2222.1978.tb00474.x","volume":"8","author":"M Viander","year":"1978","unstructured":"Viander M, Koivikko A. The seasonal symptoms of hyposensitized and untreated hay fever patients in relation to birch pollen counts: correlations with nasal sensitivity, prick tests and RAST. Clin Allergy. 1978;8:387\u201396.","journal-title":"Clin Allergy"},{"key":"1054_CR30","unstructured":"ICH E9 (R1.) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. [Internet]. European Medicines Agency; 2020 [cited 2025 December 11]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e9-r1-addendum-estimands-and-sensitivity-analysis-clinical-trials-guideline-statistical-principles-clinical-trials-step-5_en.pdf"},{"key":"1054_CR31","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.jaci.2018.12.1001","volume":"143","author":"T Biedermann","year":"2019","unstructured":"Biedermann T, Kuna P, Panzner P, Valovirta E, Andersson M, de Blay F, et al. The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial. J Allergy Clin Immunol. 2019;143:1058\u201366. e6.","journal-title":"J Allergy Clin Immunol"},{"key":"1054_CR32","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1398-9995.2006.01312.x","volume":"62","author":"GW Canonica","year":"2007","unstructured":"Canonica GW, Baena-Cagnani CE, Bousquet J, Bousquet PJ, Lockey RF, Malling HJ, et al. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy. 2007;62:317\u201324.","journal-title":"Allergy"},{"key":"1054_CR33","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1111\/all.16654","volume":"80","author":"O Pfaar","year":"2025","unstructured":"Pfaar O, M\u00f6sges R, Blaiss MS, Becker S, DuBuske L, Bernstein JA, et al. The Minimal Clinically Important Difference in Allergen Immunotherapy: An Evidence-Based Approach. Allergy. 2025;80:3369\u201376.","journal-title":"Allergy"},{"key":"1054_CR34","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/j.jaip.2021.01.035","volume":"9","author":"H Nolte","year":"2021","unstructured":"Nolte H, Waserman S, Ellis AK, Biedermann T, Wurtzen PA. Treatment Effect of the Tree Pollen SLIT-Tablet on Allergic Rhinoconjunctivitis During Oak Pollen Season. J Allergy Clin Immunol Pract. 2021;9:1871\u20138.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1054_CR35","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jaci.2010.09.034","volume":"127","author":"L Cox","year":"2011","unstructured":"Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127:S1\u201355.","journal-title":"J Allergy Clin Immunol"},{"key":"1054_CR36","unstructured":"Immunotherapy manual. [Internet]. Canadian Society of Allergy & Clinical Immunology; 2024 [cited 2025 December 15]. Available from: https:\/\/www.csaci.ca\/wp-content\/uploads\/2024\/12\/IT-manual-Dec-13_2024_CLEAN.pdf"},{"key":"1054_CR37","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/all.13317","volume":"73","author":"G Roberts","year":"2018","unstructured":"Roberts G, Pfaar O, Akdis CA, Ansotegui IJ, Durham SR, van Gerth R, et al. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018;73:765\u201398.","journal-title":"Allergy"},{"key":"1054_CR38","doi-asserted-by":"crossref","unstructured":"Stranzl T, Bernstein DI, Matsuoka T, Durham S, Maekawa Y, Sejer Andersen P et al. Consistent efficacy and safety of sublingual immunotherapy tablets across allergens and geographic regions. Allergy Asthma Proc. 2024;45:232-9.","DOI":"10.2500\/aap.2024.45.240020"}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-026-01054-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-026-01054-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-026-01054-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:27:58Z","timestamp":1791250078000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13223-026-01054-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1054"],"URL":"https:\/\/doi.org\/10.1186\/s13223-026-01054-w","relation":{},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent was obtained from each participant\u2019s legal guardian, and the trial was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. The trial protocol was reviewed and approved by an institutional review board.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R\u00e9mi Gagnon has conducted research for ALK-Abell\u00f3, AstraZeneca, GSK, DBV, Regeneron, Moderna, Novartis, Sanofi, received consultancy fees from ALK, Regeneron, Bausch Lomb, Sanofi-Genzyme, and received lecture fees from Bausch Lomb and Novartis. Monika Gappa has received lecture fees and honoraria from Aimmune, ALK, BerlinChemie, GSK, HAL, Nestle, and Regeneron-Sanofi. Terrie Dalgaard, Gry Schermann Ortving, and Hendrik Nolte are employees of ALK.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"55"}}